Date: 2018-08-31
Type of information: Series A financing round
Company: Antabio (France)
Investors: iXO Private Equity (France) IRDI SORIDEC Gestion (France) Galia Gestion (France) Omnes Capital (France) BNP Paribas Développement (France) Sham Innovation Santé (Turenne Capital) (France) and company’s historical investors including former President of OM Pharma Christophe Ricard.
Amount: € 12.5 million
Funding type: series A financing round
Planned used:
- The funding will be used to accelerate the development, up to completion of Phase 1 clinical trials, of Antabio’s novel inhibitor of bacterial metallo ß-lactamases (“MBLIs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. There are currently no marketed inhibitors of MBLs.
Others:
- • On July 12, 2018, Antabio, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced it has extended its Series A financing round with an additional €5.2 million subscribed by investment funds Omnes, BNP Paribas Développement, and Sham Innovation Santé (Turenne Capital).
- Existing shareholder Galia Gestion also participated in this extension. The second closing brings the total raised in Series A to €12.5 million.
- The €12.5 million series A financing complements the CARB-X grant of up to $8.9 million awarded to Antabio in July 2017 to support the company’s Pseudomonas Elastase Inhibitor program (PEI) for the treatment of chronic Pseudomonas infections in Cystic Fibrosis patients.
- • On October 16, 2017. Antabio announced the completion of a €7.3M series A financing with subscriptions from investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and from the company’s historical investors including former President of OM Pharma Christophe Ricard. This financing complements the recent CARB-X grant of up to $8,9 million awarded to Antabio in July 2017 to support the company’s Elastase Inhibitor program (PEI) for the treatment of chronic Pseudomonas infections in Cystic Fibrosis patients.
Therapeutic area: Rare diseases - Infectious diseases
Is general: Yes
